What is OncoResponse?
OncoResponse operates at the intersection of biotechnology and precision medicine, focusing on the identification of therapeutic candidates for patients who historically do not respond to standard immunotherapy protocols. By utilizing a proprietary human antibody platform, the company is uniquely positioned to translate complex biological insights into actionable clinical solutions. Its market position is bolstered by a robust research framework and strategic collaborations with leading academic and medical institutions, ensuring a steady pipeline of innovation aimed at extending survival rates and improving patient outcomes globally.
How much funding has OncoResponse raised?
OncoResponse has raised a total of $203.2M across 10 funding rounds:
Private Equity
$29.5M
Series A
$9.5M
Series B
$40M
Debt
$150K
Debt
$416K
Series C
$40.6M
Debt
$50M
Other Financing Round
$14M
Grant
$13M
Other Financing Round
$6M
Private Equity (2015): $29.5M, investors not publicly disclosed
Series A (2015): $9.5M led by Canaan Partners, ARCH Venture Partners, and MD Anderson
Series B (2018): $40M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $416K backed by PPP
Series C (2021): $40.6M with participation from Canaan Partners, Magnetar Group, Redmile Group, BERING CAPITAL, Qatar Investment Authority, 3B Future Health Fund, Yonjin Venture, ARCH VENTURE PARTNERS, and RiverVest Venture Partners
Debt (2022): $50M led by Oxford Finance
Other Financing Round (2023): $14M supported by ARCH Venture Partners, RiverVest Venture Partners, and Canaan Partners
Grant (2023): $13M featuring Cancer Prevention and Research Institute of Texas
Other Financing Round (2025): $6M, investors not publicly disclosed
Key Investors in OncoResponse
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Canaan Partners
Canaan is an early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages in areas such as enterprise software, fintech, consumer, biopharma, and digital health.
RiverVest Venture Partners
RiverVest is a prominent venture capital firm focused on building life science companies to meet significant unmet medical needs, supporting entrepreneurs through a commitment to science, strategy, and innovation.
What's next for OncoResponse?
With the recent strategic investment, OncoResponse is well-positioned to transition its lead candidates through critical clinical development phases. The company's roadmap likely involves expanding its therapeutic portfolio and deepening its research capabilities to address broader oncology indications. As the firm continues to scale, the focus will remain on validating its antibody platform's efficacy in human trials, potentially setting the stage for future licensing agreements or strategic partnerships that could further solidify its influence in the biopharmaceutical sector.
See full OncoResponse company page
